Page last updated: 2024-12-05

dicyclohexylcarbodiimide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DCC is a widely used reagent in organic synthesis, particularly for peptide coupling reactions. It is a powerful dehydrating agent, capable of activating carboxylic acids to form reactive intermediates. DCC synthesis involves the reaction of N,N'-dicyclohexylurea with phosgene. While a very effective coupling reagent, DCC has some drawbacks. Its use can lead to the formation of side products, including N-acylureas. Additionally, DCC is difficult to remove from reaction mixtures. Despite these limitations, DCC remains an important reagent for the synthesis of peptides, amides, esters, and other functional groups. Its ability to efficiently form peptide bonds makes it a cornerstone in the study of peptide chemistry, protein synthesis, and development of new therapeutic agents.'

1,3-dicyclohexylcarbodiimide : A carbodiimide compound having a cyclohexyl substituent on both nitrogen atoms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10868
CHEMBL ID162598
CHEBI ID53090
SCHEMBL ID303
MeSH IDM0006313

Synonyms (142)

Synonym
unii-0t1427205e
ec 208-704-1
4-12-00-00072 (beilstein handbook reference)
ccris 9266
0t1427205e ,
hsdb 8049
cyclohexanamine, n,n'-methanetetraylbis-
nsc53373
nsc-53373
dccd
carbodicyclohexylimide
nsc-30022
DCC ,
dicylcohexylcarbodiimide
nsc30022
538-75-0
1,3-dicyclohexylcarbodiimide
dicyclohexylcarbodiimide ,
cyclohexanamine,n'-methanetetraylbis-
carbodiimide, dicyclohexyl-
dcci
nsc-57182
nsc57182
carbodiimide,dicyclohexyl
inchi=1/c13h22n2/c1-3-7-12(8-4-1)14-11-15-13-9-5-2-6-10-13/h12-13h,1-10h
n,n'-dicyclohexylcarbodiimide
NCGC00091497-01
brn 0610662
bis(cyclohexyl)carbodiimide
n,n'-methanetetraylbiscyclohexaamine
ai3-08191
cyclohexaamine, n,n'-methanetetraylbis-
einecs 208-704-1
nsc 30022
dcc, 99%
dcc, 1.0 m in methylene chloride
NCGC00091497-02
dicyclohexyl-carboxydilmide
CHEBI:53090 ,
dicyclohexylmethanediimine
D0436
D0437
n,n'-dicyclohexylmethanediimine
STL089892
n,n'-dicyclohexyl-carbodiimide
CHEMBL162598
dicyclohexyl-carbodiimide
AKOS000120067
NCGC00091497-03
NCGC00091497-04
n,n'-dicyclohexylcarbodiimid
dtxcid003817
cas-538-75-0
NCGC00257167-01
dtxsid1023817 ,
tox21_303237
tox21_203000
NCGC00260545-01
BBL012208
n,n'-dicyclohexylcarbodiimide (dcc)
c13h22n2
n,n'-methanediylidenedicyclohexanamine
FT-0629452
n,n-dicyclohexylcarbodiimide
EPITOPE ID:114067
dicyclohexylcarbodiimide [mi]
dicyclohexylcarbodiimide [hsdb]
BP-13398
us8815951, dicyclohexylcarbodiimide
us8815951, n/a
bdbm129231
n,n-dichyclohexylcarbodiimide
AM83818
SCHEMBL303
n,n'-dicyclohexylcarbodimide
dicyclohexylcarbodimide
dicyclohexyl carbodimide
n,n'-methanediylidene-dicyclohexanamine
1,3-dicylcohexylcarbodiimide
n,n'-dicyclohexyl carbodiimide
1,3-dicyclohexylcarbodiimid
dicylohexyl-carbodiimide
dicylcohexylcarbodimide
dicyclohexylcarbo-diimide
dicyclo-hexylcarbodiimide
1,3-dicyclohexyl carbodiimide
n,n'dicyclohexylcarbodiimide
1, 3-dicyclohexylcarbodiimide
n,n'-dicylcohexylcarbodiimide
1,3-di-cyclohexyl carbodiimide
n.n' - dicyclohexylcarbodiimide
1,n'-dicyclohexylcarbodimide
1,3-dicyclohexyl- carbodiimide
dicyclohexylcarbodiimid
1,3-dicyclohexylcarbo-diimide
dicyclohexyicarbodiimide
n-(n-cyclohexylcarboximidoyl)cyclohexanamine
1.3-dicyclohexylcarbodiimide
dicyclohexyl carbodiimide
n-((cyclohexylimino)methylene) cyclohexanamine
dicylohexylcarbodiimide
n,n'-dicyclo hexylcarbodiimide
1,3dicyclohexylcarbodiimide
1,3-dicyclo hexyl carbodiimide
1,3- dicyclohexylcarbodiimide
1,3-dicyclo-hexylcarbodiimide
n,n'- dicyclohexyl carbodiimide
n, n'-dicyclohexylcarbodimide
n,n'-dicyclo hexyl carbodiimide
n, n'-dicyclohexyl carbodiimide
dicyclohexylcarbod iimide
n, n'dicyclohexylcarbodimide
n, n'-dicyclohexylcarbodiimide
n-((cyclohexylimino)methylene)cyclohexanamine
n.n'-dicyclohexylcarbodiimide
dicyclohexylcarbodi-imide
dicyclohexyl carbo diimide
n,n'-dicyclo-hexylcarbodiimide
dicyciohexylcarbodiimide
1,3-dicyclohexyl-carbodiimide
1,3-dicyclohexyl carbo-diimide
1,3-dicyclohexylcarbodimide
n,n,-dichyclohexyl-carbodiimide
n,n'-dicyclohexyl carbodimide
n,n'-dicylohexylcarbodiimide
1.3-dicyclohexylcarbodimide
Q-200966
n,n'-methanetetraylbiscyclohexanamine
methanediimine, n,n'-dicyclohexyl-
n,n-dicyclohexylcarbodiimide(dcc)
F0001-1397
CS-W020097
mfcd00011659
dcc, puriss., >=99.0% (gc)
C93487
dicyclimide;1,3-dicyclohexylcarbodiimide;n,n-dicyclohexylcarbodiimide;n,n'-methanediylidenedicyclohexanamine
Q306565
dicyclohe-xylcarbodiimide
dcc crosslinker
EN300-20280
Z104477564
HY-Y1092

Research Excerpts

Overview

N,N-Dicyclohexylcarbodiimide (DCCD) is a classical inhibitor of the F0F1-ATP synthase. It covalently binds to the highly conserved carboxylic acid of the proteolipid subunit (c subunit) in F0.

ExcerptReferenceRelevance
"N,N-Dicyclohexylcarbodiimide (DCCD) is a classical inhibitor of the F0F1-ATP synthase (F0F1), which covalently binds to the highly conserved carboxylic acid of the proteolipid subunit (c subunit) in F0. "( Single-molecule analysis of F0F1-ATP synthase inhibited by N,N-dicyclohexylcarbodiimide.
Noji, H; Toei, M, 2013
)
1.19
"Dicyclohexylcarbodiimide (DCCD) is a carboxyl group modifier and it is an inhibitor of various ATPases. "( Effect of dicyclohexylcarbodiimide (DCCD) on transport parameters in the frog cornea epithelium.
Carrasquer, G; Dinno, MA; Li, M, 2000
)
2.15
"Dicyclohexylcarbodiimide is a commonly used coupling agent found in protein synthesis. "( Contact allergic dermatitis to dicyclohexylcarbodiimide used in protein synthesis.
Adams, RM; Hoffman, TE, 1989
)
2.01
"Dicyclohexylcarbodiimide (DCCD) is a potent stimulant of superoxide generation in guinea-pig peritoneal and bovine blood neutrophils. "( Activation of guinea-pig and bovine neutrophil NADPH oxidase by N,N'-dicyclohexylcarbodiimide.
Aviram, A; Aviram, I, 1985
)
1.95

Effects

N,N'-dicyclohexylcarbodiimide (DCCD) has been reported to inhibit steady-state proton translocation by cytochrome bc(1) and b(6)f complexes without significantly altering the rate of electron transport.

ExcerptReferenceRelevance
"N,N'-dicyclohexylcarbodiimide (DCCD) has been reported to inhibit steady-state proton translocation by cytochrome bc(1) and b(6)f complexes without significantly altering the rate of electron transport, a process referred to as decoupling. "( Aspartate-187 of cytochrome b is not needed for DCCD inhibition of ubiquinol: cytochrome c oxidoreductase in Rhodobacter sphaeroides chromatophores.
Crofts, AR; Shinkarev, VP; Takahashi, E; Ugulava, NB; Wraight, CA, 2000
)
0.82
"N,N'-dicyclohexylcarbodiimide (DCCD) has been reported to inhibit proton translocation by cytochrome bc(1) and b(6)f complexes without significantly altering the rate of electron transport, a process referred to as decoupling. "( DCCD inhibits the reactions of the iron-sulfur protein in Rhodobacter sphaeroides chromatophores.
Crofts, AR; Shinkarev, VP; Ugulava, NB; Wraight, CA, 2000
)
0.82
"N,N'-Dicyclohexylcarbodiimide (DCC) has been previously shown to inhibit the amine transporter from chromaffin granules [Gasnier, B., Scherman, D., & Henry, J.P. "( Covalent modification of the amine transporter with N,N'-dicyclohexylcarbodiimide.
Gabay, T; Schuldiner, S; Stern-Bach, Y; Suchi, R, 1991
)
1.04

Actions

ExcerptReferenceRelevance
"Dicyclohexylcarbodiimide did not inhibit the adenosine triphosphatase activity in membrane particles."( Membrane-associated, energy-linked reactions in Bdellovibrio bacteriovorus.
Friedberg, D; Friedberg, I, 1976
)
0.98

Treatment

ExcerptReferenceRelevance
"Dicyclohexylcarbodiimide treatment mimics the effect of the Mg2+ATPase in the case of respiration-driven reactions."( Energy transduction in Escherichia coli. The role of the Mg2+ATPase.
Rosen, BP; Tsuchiya, T, 1975
)
0.98

Bioavailability

ExcerptReferenceRelevance
"2h) and low absolute bioavailability (1."( Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
Chaturvedi, V; Dasgupta, A; Gupta, AD; Jaiswal, S; Kashyap, VK; Khan, SR; Krishnan, MY; Lal, J; Roy, KK; Saxena, AK; Sharma, A; Sharma, SK; Singh, S; Sinha, S; Srivastava, R, 2015
)
0.42
" Its bioavailability at an oral dose of 2 mg/kg was 15%."( Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.
Beuerman, RW; Cao, D; Corkran, HM; Dick, T; Koh, JJ; Lakshminarayanan, R; Lim, F; Lin, S; Liu, S; Mukherjee, D; Stocker, BL; Tan, DTH; Tan, DZ; Tan, JK; Timmer, MSM; Zou, H, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" The assembly of the mutant c-subunit requires an increased gene dosage [Jans, Fimmel, Langman, James, Downie, Senior, Ash, Gibson & Cox (1983) Biochem."( Oxidative phosphorylation by mutant Escherichia coli membranes with impaired proton permeability.
Cox, GB; Fimmel, AL; Gibson, F; Jans, DA; Langman, L; Senior, AE, 1983
)
0.27
" Quantitative analyses showed that the dose-response relationship for each chemical followed a cubic trend."( Acute stress modulates the irritant component of sensitizers in allergic contact dermatitis: implications for exposure assessment.
Brumbaugh, K; Flint, MS; Salmen, RR; Tinkle, SS, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
peptide coupling reagentA reagent used to couple amino acids during artificial peptide synthesis.
ATP synthase inhibitorA mitochondrial respiratory-chain inhibitor that interferes with the action of ATP synthase.
cross-linking reagentA reagent with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between macromolecules, principally side chains of amino acids in proteins, allowing the locations of naturally reactive areas within the proteins to be identified.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
carbodiimideAny organonitrogen compound that consists of two primary amino groups joined to a central carbon atom via N=C linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
NAD phosphorylation and transhydrogenation510
NAD phosphorylation and dephosphorylation312
ATP biosynthesis4015

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency14.16230.007215.758889.3584AID1224835
interleukin 8Homo sapiens (human)Potency53.08040.047349.480674.9780AID651758
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency34.42153.189029.884159.4836AID1224846
SMAD family member 2Homo sapiens (human)Potency55.47710.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency55.47710.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency57.82820.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency15.11730.000221.22318,912.5098AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743054; AID743063
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency79.43280.00137.762544.6684AID2120
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency14.56220.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency17.83290.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency12.19720.000417.946075.1148AID1346784
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency20.32470.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency34.47980.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency13.00090.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency9.35920.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency33.55210.375827.485161.6524AID588526; AID588527
pregnane X nuclear receptorHomo sapiens (human)Potency57.99320.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency16.28060.000229.305416,493.5996AID1259244; AID1259248; AID588514; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency26.82320.001024.504861.6448AID588535; AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency12.88240.001019.414170.9645AID588536; AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency42.23950.023723.228263.5986AID588541; AID588543
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency2.86130.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency29.68960.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency43.646519.739145.978464.9432AID1159509
Histone H2A.xCricetulus griseus (Chinese hamster)Potency113.00400.039147.5451146.8240AID1224845
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency70.79460.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency10.17510.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency8.43310.000627.21521,122.0200AID651741; AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency3.62530.00798.23321,122.0200AID2546; AID2551
lethal factor (plasmid)Bacillus anthracis str. A2012Potency3.98110.020010.786931.6228AID912
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency35.37490.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency24.33270.002319.595674.0614AID651631; AID651743; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency35.37490.001551.739315,848.9004AID1259244
Nuclear receptor ROR-gammaHomo sapiens (human)Potency18.83360.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (134)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1333159Antimycobacterial activity against Mycobacterium smegmatis MC2 155 assessed as inhibition of respiratory ATP synthesis by measuring ATP level at 800 ug/ml measured after 1 hr by luciferase reporter gene assay (Rvb = 90.6%)2016European journal of medicinal chemistry, Nov-10, Volume: 123Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.
AID1192647Inhibition of Mycobacterium smegmatis TMC 607 ATP synthase at 100 uM incubated for 10 mins prior to NADH addition measured after 1 hr by luminescence assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
AID374184Antimicrobial activity against 3 weeks old culture of Mycobacterium tuberculosis H37Ra assessed as colony forming unit in hypoxic condition at 10.3 ug/ml for 3 hrs2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis.
AID1333280Antimycobacterial activity against Mycobacterium smegmatis MC2 155 assessed as induction of ATP leakage by measuring increase in extracellular ATP level at 800 ug/ml measured up to 9 hrs by luciferase reporter gene assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.
AID1333277Antimycobacterial activity against Mycobacterium smegmatis MC2 155 assessed as inhibition of respiratory ATP synthesis by measuring ATP level at 800 ug/ml measured after 9 hrs by luciferase reporter gene assay (Rvb = 212.7%)2016European journal of medicinal chemistry, Nov-10, Volume: 123Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.
AID374183Antimicrobial activity against 3 weeks old culture of Mycobacterium tuberculosis H37Ra assessed as colony forming unit in aerobic condition at 10.3 ug/ml for 3 hrs2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis.
AID1861243Inhibition of PTPC in human AC16 cells at 1 uM measured by calcein-cobalt assay relative to control
AID1192657Inhibition of Swiss mouse liver ATP synthase at 100 uM after 1 hr2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
AID104791Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives.
AID1333274Antimycobacterial activity against Mycobacterium smegmatis MC2 155 assessed as inhibition of respiratory ATP synthesis by measuring ATP level at 800 ug/ml measured after 6 hrs by luciferase reporter gene assay (Rvb = 152%)2016European journal of medicinal chemistry, Nov-10, Volume: 123Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.
AID1192655Inhibition of Mycobacterium tuberculosis H37Rv ATP synthase assessed as reduction in total ATP content at 100 uM after 18 hrs by bead-vortexing settling method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
AID1333271Antimycobacterial activity against Mycobacterium smegmatis MC2 155 assessed as inhibition of respiratory ATP synthesis by measuring ATP level at 800 ug/ml measured after 3 hrs by luciferase reporter gene assay (Rvb = 158.3%)2016European journal of medicinal chemistry, Nov-10, Volume: 123Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.
AID1192660Bactericidal activity against non-replicating Mycobacterium tuberculosis H37Rv Wayne model under hypoxic/oxygen depleted conditions assessed as log reduction at 100 ug/ml after 4 days by serial dilution assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
AID232758Selectivity index measured as the ratio of CC50/IC50 values.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives.
AID1192659Bactericidal activity against non-replicating Mycobacterium tuberculosis H37Rv Wayne model under hypoxic/oxygen depleted conditions assessed as log reduction after 4 days by serial dilution assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
AID106037Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,315)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990809 (61.52)18.7374
1990's302 (22.97)18.2507
2000's127 (9.66)29.6817
2010's68 (5.17)24.3611
2020's9 (0.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.58 (24.57)
Research Supply Index7.23 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index87.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (51.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews31 (2.25%)6.00%
Case Studies9 (0.65%)4.05%
Observational0 (0.00%)0.25%
Other1,335 (97.09%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]